Chinese vaccine company Sinovac Biotech Ltd announced on Monday that its newly developed adsorbed tetanus vaccine has officially obtained approval from the National Medical Products Administration, marking a milestone in the company's push to expand its presence in the trauma care sector.

The vaccine features aluminum hydroxide adjuvants with a particle size of just 300 nanometers, far smaller than the 1 to 10 micrometer range of traditional adjuvants. This innovation enhances antigen adsorption efficiency and boosts the overall stability of the product, addressing two critical factors in vaccine efficacy and shelf-life.

Beyond the adjuvant upgrade, Sinovac also noted that an enhanced purification process has raised the immunogenicity of the vaccine’s active ingredient, the part that triggers the body's immune response, further strengthening its protective effect.

In recent years, Sinovac has been actively expanding its footprint in the trauma care sector. The adsorbed tetanus vaccine is a major step forward for its "trauma combination product" plan. In addition to this vaccine, Sinovac is advancing clinical research on SNA02-48, an anti-tetanus toxin monoclonal antibody injection.